We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Mirum Pharmaceuticals Inc
2 own
3 watching
Current Price
$0
$0.23
(0.98%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
864.39M
52-Week High
30.545
52-Week Low
17.315
Average Volume
0.07M
Dividend Yield
--
P/E Ratio
--
Market Capitalization864.39M52-Week High30.54552-Week Low17.315Average Volume0.07MDividend Yield--P/E Ratio--What does the Mirum Pharmaceuticals Inc do?
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Read More
How much money does Mirum Pharmaceuticals Inc make?
News & Events about Mirum Pharmaceuticals Inc.
Business Wire
21days ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2023, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common stock and 12,000 restricted stock units (RSUs) to four...
Business Wire
23days ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview of the companys plans, estimated revenue and net product sales for Q4 and full year 2022 ahead of its presentation at the 41st Annual J.P. Morgan Healthcare Conference. 2022 was a year of strong commercial performance and continued...
Business Wire
1month ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in...
Business Wire
1month ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. The approval follows...
Ticker Report
2 months ago
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM Get Rating) Director Niall Odonnell sold 174,121 shares of the companys stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $19.99, for a total transaction of $3,480,678.79. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Mirum Pharmaceuticals Inc share price today?
Can Indians buy Mirum Pharmaceuticals Inc shares?
How can I buy Mirum Pharmaceuticals Inc shares from India?
Can Fractional shares of Mirum Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Mirum Pharmaceuticals Inc stocks?
What is today’s traded volume of Mirum Pharmaceuticals Inc?
What is today’s market capitalisation of Mirum Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Mirum Pharmaceuticals Inc?
What percentage is Mirum Pharmaceuticals Inc down from its 52-Week High?
What percentage is Mirum Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$0
$0.23
(0.98%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.